Prostate Cancer Update 2022Catalona, William J.Dahl, Douglas M.Liauw, Stanley L.Loeb, StacyNadler, Robert B.Szmulewitz, RussellAUANews
The objective of the French Urology Association Cancer Committee is to propose an update of the recommendations for the management of prostate cancer. Methods A systematic review of the literature from 2020 to 2022 was conducted by the CCAFU on the elements of therapeutic management of metastatic ...
markers were further filtered to select cell surface markers (SPC42>2). PCa: Prostate cancer; NC: Non-cancer; SPC: Surface prediction consensus42.P-values from a two-sided Mann–WhitneyUtest.dTumor markers with predicted cell surface localization from (c). Proteins are annotated with the freq...
All documents can be accessed on the EAU website: http://uroweb.org/guideline/prostate-cancer/. 1.4 Publication history and summary of changes 1.4.1 Publication history The EAU PCa Guidelines were first published in 2001. This 2022 document presents a limited update of the 2021 EAU-EANM-ESTRO...
The ZERO Prostate Cancer Support Community connects patients, families, friends and caregivers to enhance the quality of life for all those affected by prostate cancer. This community is sponsored by ZERO Prostate Cancer, an Inspire trusted partner.
WebMD's slideshow covers prostate cancer: who's at risk, symptoms, tests, staging, treatments, survival, and foods that may help lower your risk for prostate cancer.
All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications, according to Emmanuel S. Antonarakis, MD...
A PI-RADS score 1 or 2 appears less likely to miss existing prostate cancer, although a small amount of csCa can be overlooked. In case of clinical suspicion or elevated PSA density and PI-RADS score 1 or 2, an individual decision has to be taken if biopsy is necessary or if monitorin...
2022 Update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 2023;84:191–206. Article PubMed Google Scholar Gleave M, Goldenberg SL, Bruchovsky N, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer ...
Prostate Cancer Prostatic Dis. 2022; https://doi.org/10.1038/s41391-022-00549-y Visser WCH, de Jong H, Steyaert S, Melchers WJG, Mulders PFA, Schalken JA. Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:583–9. ...